Fuzhou Hai Wang Fu Yao Pharmaceutical Co., Ltd. romanized
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference cdb04f99cc
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/13 06:42.
Drug filings
4 acceptance records as first applicant, grouped into 4 source drug names. Source data as of 2026/11/13 06:42.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
Bumetanide Injection 1 records · Latest accepted 2026/04/30
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2650108 | Supplement | 2026/04/30 | Fuzhou Hai Wang Fu Yao Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Folic Acid Tablets 1 records · Latest accepted 2025/12/18
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2550404 | Supplement | 2025/12/18 | Fuzhou Hai Wang Fu Yao Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Atropine Sulfate Injection 1 records · Latest accepted 2023/07/29
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2350603 | Supplement | 2023/07/29 | Fuzhou Hai Wang Fu Yao Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Sildenafil Citrate Oral Disintegrating Tablets 1 records · Latest accepted 2023/01/12
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2300108 | Generic | 2023/01/12 | Fuzhou Hai Wang Fu Yao Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Changes in the last 90 days
0 events from 2026/08/16 to 2026/11/13. CDE data as of 2026/11/13 06:42; NMPA data as of 2026/11/12 18:32.
This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
- No matching records were found in the currently loaded source data; coverage dates are listed below.
Under review
2 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/13 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Bumetanide Injection | CYHB2650108 | Supplement | 2026/04/30 | Fuzhou Hai Wang Fu Yao Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| Folic Acid Tablets | CYHB2550404 | Supplement | 2025/12/18 | Fuzhou Hai Wang Fu Yao Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Catalogue holder records
3 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/13 06:39. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | Approval number | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Atropine Sulfate Injection | Fuzhou Hai Wang Fu Yao Pharmaceutical Co., Ltd. romanized | Fuzhou Hai Wang Fu Yao Pharmaceutical Co., Ltd. romanized | 国药准字H20247198 | 2024/08/23 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Sildenafil Citrate Oral Disintegrating Tablets | Fuzhou Hai Wang Fu Yao Pharmaceutical Co., Ltd. romanized | Fuzhou Hai Wang Fu Yao Pharmaceutical Co., Ltd. romanized | 国药准字H20244332 | 2024/06/28 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| 诺氟沙星胶囊 · No verified English name | Fuzhou Hai Wang Fu Yao Pharmaceutical Co., Ltd. romanized | Fuzhou Hai Wang Fu Yao Pharmaceutical Co., Ltd. romanized | 国药准字H35020296 | 2020/12/29 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
6 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/13 06:41.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| 新福菌素 · No verified English name | Fuzhou Hai Wang Fu Yao Pharmaceutical Co., Ltd. romanized | Y20190008518 | A | 2024/01/17 | CDE ↗ |
| 盐酸法舒地尔 · No verified English name | Fuzhou Hai Wang Fu Yao Pharmaceutical Co., Ltd. romanized | Y20190005808 | A | — | CDE ↗ |
| 吗替麦考酚酯 · No verified English name | Fuzhou Hai Wang Fu Yao Pharmaceutical Co., Ltd. romanized | Y20190005113 | A | — | CDE ↗ |
| 呋咱甲氢龙 · No verified English name | Fuzhou Hai Wang Fu Yao Pharmaceutical Co., Ltd. romanized | Y20190002827 | A | — | CDE ↗ |
| 替米沙坦 · No verified English name | Fuzhou Hai Wang Fu Yao Pharmaceutical Co., Ltd. romanized | Y20190001323 | A | — | CDE ↗ |
| 匹伐他汀钙 · No verified English name | Fuzhou Hai Wang Fu Yao Pharmaceutical Co., Ltd. romanized | Y20170000136 | I | — | CDE ↗ |
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
5 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/13 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Sildenafil Citrate Oral Disintegrating Tablets | CYHB2600337 | Supplement | 2026/02/11 | Shenzhen Hai Wang Pharmaceuticals Technology Research Institute Co., Ltd. romanized; Fuzhou Hai Wang Fu Yao Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| Multiple Electrolyte Additive For Injection | CYHB2500374 | Supplement | 2025/02/25 | Beijing Yi Ling Pharmaceuticals Technology Development Co., Ltd. romanized; Fuzhou Hai Wang Fu Yao Pharmaceutical Co., Ltd. romanized; Hebei Tian Cheng Pharma Co., Ltd. romanized | CDE ↗ |
| Sodium Bicarbonate Ringer’s Injection | CYHS2300096 | Generic | 2023/01/11 | Fujian Fu Xing Pharma Co., Ltd. romanized; Fuzhou Hai Wang Fu Yao Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| Sodium Bicarbonate Ringer’s Injection | CYHS2300095 | Generic | 2023/01/11 | Fujian Fu Xing Pharma Co., Ltd. romanized; Fuzhou Hai Wang Fu Yao Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| Doxofylline Injection | CYHB2201712 | Supplement | 2022/09/21 | Wei Sheng Yuan (Xiamen) Bio Technology Co., Ltd. romanized; Fuzhou Hai Wang Fu Yao Pharmaceutical Co., Ltd. romanized | CDE ↗ |
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/13 06:42
- Chemical-drug catalogue
- Last successful update: 2026/11/13 06:39
- Full API register
- Last successful update: 2026/11/13 06:41
- NMPA drug delivery notices
- Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete
First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.